NEWS
Mesoblast rattles tin for at least $37m with Bell Potter
MELBOURNE: Mesoblast, the local biotech developing treatments for cardiovascular disease and back pain, ... read more
Brookfield set to buy back debt in Healthscope deal
MELBOURNE: Canadian private equity fund Brookfield is understood to have bought back about ... read more